

Remarks

Claims 1-30 are pending in the subject application. By this Amendment, Applicants have amended claims 1, 4, 8, 10, and 13-24 and added new claims 31-54. Support for the amendments and new claims can be found throughout the subject specification and in the claims as originally filed (see, for example, pages 2-6). Entry and consideration of the amendments presented herein is respectfully requested. Accordingly, claims 1-54 are currently before the Examiner. Favorable consideration of the pending claims is respectfully requested.

The specification and claims are objected to because of informalities. The Examiner indicates that the term “bupropion” is misspelled. Applicants gratefully acknowledge the Examiner’s careful review of the specification and claims. In accordance with the Examiner’s suggestion, Applicants have replaced the word “bupropion” with “bupropion”. Accordingly, reconsideration and withdrawal of the objection is respectfully requested.

Claims 1-7, 13, 14, 17, 18, 20, and 25-27 are rejected under 35 U.S.C. § 112, first paragraph, as nonenabled by the subject specification. The Office Action indicates that the specification is enabled for the “treatment of cognitive dysfunction” but is not enabled for the “prevention of cognitive dysfunction.” Applicants respectfully assert that the claims are enabled by the subject specification; however, in the interest of advancing prosecution in this matter, the claims have been amended to recite the treatment or amelioration of a medication-induced cognitive dysfunction. Accordingly, reconsideration and withdrawal of the rejection under 35 U.S.C. § 112, first paragraph, is respectfully requested.

Claims 1, 2, 10, 17, and 25 are rejected under 35 U.S.C. § 102(a) as anticipated by Michelson *et al.* (2003). The Office Action states that Michelson *et al.* teach that atomoxetine is effective for treatment of attention-deficit/hyperactivity disorder (ADHD). In addition, the Office Action indicates that Michelson *et al.* teach that ADHD is a psychiatric disorder characterized by difficulties sustaining attention and difficulties with impulse control. Finally, it is noted that Michelson *et al.* teach that atomoxetine was administered 60 mg of daily dosage and increased to 90 mg/day and to 12 mg/day. The Office Action indicates that the teaching of Michelson *et al.* that atomoxetine provided an efficacious treatment of ADHD characterized by difficulties sustaining attention clearly

anticipates the claimed invention. Applicants respectfully assert that the Michelson *et al.* reference does not anticipate the claimed invention.

As the Patent Office is aware, a claim is anticipated only if each and every element as set forth in the claim is found, either expressly or inherently described, in a single prior art reference.” *Verdegaal Bros. v. Union Oil Co. of California*, 814 F.2d 628, 631, 2 USPQ2d 1051, 1053 (Fed. Cir. 1987). In this case, it is respectfully submitted that the cited reference fails to teach each and every element of the claimed invention. For example, Michelson *et al.* fails to teach: 1) the treatment or amelioration of medication-induced cognitive dysfunction; 2) the treatment or amelioration of perioperative cognitive dysfunction; 3) the treatment or amelioration of cognitive dysfunction associated with, or arising from, a stressful situation; or 4) the optimization of cognitive dysfunction in individuals whose cognitive function tests in the normal range. Rather, the reference teaches the administration of atomoxetine for the treatment of ADHD, and it is respectfully submitted that the individuals with ADHD have abnormal cognitive function, not normal cognitive function (see, for example, Spencer *et al.*, *J. Clin. Psychiatry*, 2002, 63 (Supp. 12):3-9, discussing the Model of Executive Dysfunctions at page 6, a copy of which is attached hereto). Accordingly, reconsideration and withdrawal of the rejection under 35 U.S.C. § 102(a) is respectfully requested as the cited reference fails to teach each of the limitations of the rejected claims.

Claims 3, 13, 16, 18, 23, and 24 are rejected under 35 U.S.C. § 103(a) as obvious over Michelson *et al.* (2003). The Office Action states that Michelson *et al.* teach that atomoxetine is effective for treatment of ADHD, that ADHD is a psychiatric disorder characterized by difficulties sustaining attention and difficulties with impulse control, and that atomoxetine was administered 60 mg of daily dosage and increased to 90 mg/day and to 120 mg/day. The Office Action notes that Michelson *et al.* teach that bupropion, an antidepressant, is a current therapy involving treatment of ADHD. Applicants respectfully assert that the claimed invention is not obvious over the cited reference.

As the Patent Office is aware, all the claim limitations must be taught or suggested by the prior art in order to establish the *prima facie* obviousness of a claimed invention. *In re Royka*, 490 F.2d 981, 180 U.S.P.Q. 580 (C.C.P.A. 1974). As noted above, Michelson *et al.* fails to teach: 1) the treatment or amelioration of medication-induced cognitive dysfunction; 2) the treatment or

amelioration of perioperative cognitive dysfunction; 3) the treatment or amelioration of cognitive dysfunction associated with, or arising from, a stressful situation; or 4) the optimization of cognitive dysfunction in individuals whose cognitive function tests in the normal range. As such, it is respectfully submitted that the Michelson *et al.* fails to render the claimed invention *prima facie* obvious and reconsideration and withdrawal of the rejection is respectfully requested.

Claims 4-9, 11, 12, 14, 15, 19-22, and 26-30 are rejected under 35 U.S.C. § 103(a) as obvious over Bymaster *et al.* (2002) in view of Sawaguchi *et al.* (1991) and Branconnier (1983). The Office Action states that Bymaster *et al.* teach that atomoxetine increases catecholamine in prefrontal cortex (PFC), a region involved in attention and memory in ADHD and teach that atomoxetine increase dopamine concentration in PFC 3-fold, but does not alter dopamine in stratum. The Office Action indicates Sawaguchi *et al.* teach that the PFC is involved in the cognitive process or working memory and that the activation of dopamine receptors is critical for the memory processes mediated by the primate PFC. The Office Action asserts that Branconnier teaches that bupropion improves cognition. Applicants respectfully assert that the claimed invention is not obvious over the cited references.

As previously noted, all the claim limitations must be taught or suggested by the prior art in order to establish the *prima facie* obviousness of a claimed invention (*In re Royka*, 490 F.2d 981, 180 U.S.P.Q. 580 (C.C.P.A. 1974)). Applicants note that Bymaster *et al.* fail to teach: 1) the treatment or amelioration of medication-induced cognitive dysfunction; 2) the treatment or amelioration of perioperative cognitive dysfunction; 3) the treatment or amelioration of cognitive dysfunction associated with, or arising from, a stressful situation; or 4) the optimization of cognitive dysfunction in individuals whose cognitive function tests in the normal range. Sawaguchi *et al.* (1991) and Branconnier (1983) do not cure these defects in the teachings of Bymaster *et al.* Thus, it is respectfully submitted that the combination of Bymaster *et al.* (2002) in view of Sawaguchi *et al.* (1991) and Branconnier (1983) fails to render the claimed invention *prima facie* obvious and reconsideration and withdrawal of the rejection is respectfully requested.

As the Patent Office is also aware, one skilled in the art must have a reasonable expectation of success in carrying out the claimed method. See *Medichem*, 437 F.3d at 1164; *Noelle v. Lederman*, 355 F.3d 1343, 1351-52 (Fed.Cir.2004); *Brown & Williamson Tobacco Corp. v. Philip*

Morris, Inc., 229 F.3d 1120, 1121 (Fed.Cir.2000). In the case of the rejections of record, it is respectfully submitted that the teachings relied upon in establishing the rejection would not have provided one of ordinary skill in the art with a reasonable expectation of successfully carrying out the claimed invention, particularly in view of the teachings of Braconnier. In particular, it is respectfully submitted that the teachings of Braconnier do not support the assertion that “Braconnier teaches that bupropion improves cognition.” Braconnier recites four treatment groups receiving bupropion (150 mg/day), bupropion (450 mg/day), imipramine (150 mg/day), or placebo, respectively, and states that “[c]ognition improved equally in all groups” (*see* Braconnier abstract). Further, Braconnier teaches that no significant differences were observed between treatment groups and that the general cognitive increase was not due to a “pharmacological effect”, but rather to a practice effect (*see* pages 131, “Cognitive Performance and page 132, column 2, paragraph 2). In other words, all patients became more adept not due to bupropion, but rather due to increasing exposure to the cognitive tests themselves. Accordingly, it is respectfully submitted that one skilled in the art would not have been motivated to administer bupropion for the improvement of cognition as its effects were not pharmacological in nature and because no statistical difference between treatment groups were associated with its administration. Furthermore, such teachings would not have provided one skilled in the art with a reasonable expectation of success in practicing the claimed invention. Accordingly, reconsideration and withdrawal of the rejection is respectfully requested.

It should be understood that the amendments presented herein have been made solely to expedite prosecution of the subject application to completion and should not be construed as an indication of Applicants’ agreement with or acquiescence in the Examiner’s position. Applicants expressly reserve the right to pursue the invention(s) disclosed in the subject application, including any subject matter canceled or not pursued during prosecution of the subject application, in a related application.

In view of the foregoing remarks and amendments to the claims, Applicants believe that the currently pending claims are in condition for allowance, and such action is respectfully requested.

The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Applicants invite the Examiner to call the undersigned if clarification is needed on any of this response, or if the Examiner believes a telephonic interview would expedite the prosecution of the subject application to completion.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Attachment: Spencer *et al.*, 2002

Overview and Neurobiology of Attention-Deficit/Hyperactivity Disorder

Thomas J. Spencer, M.D.; Joseph Biederman, M.D.;
Timothy E. Wilens, M.D.; and Stephen V. Faraone, Ph.D.

Although attention-deficit/hyperactivity disorder (ADHD) impairs millions of people worldwide, both the prevalence and existence of the disorder are being reevaluated at the phenotypic level. To safeguard against overdiagnosis, the *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition (DSM-IV), demands that individuals with ADHD have pervasive impairment, that is, impairment in more than 1 setting. However, the appropriateness of the DSM-IV classification of ADHD is also undergoing reevaluation. Like the symptoms of a developmental disability, the symptoms of ADHD must be evaluated in the context of age-based norms; therefore, the current criteria for ADHD, which are not age-referenced, may minimize the rate of persistence of ADHD into adulthood. In an effort to better understand the pathophysiology of ADHD, recent research has focused on identifying the etiology of ADHD. These studies have revealed that the disorder is highly heritable and may be associated with neurobiological deficits in the prefrontal cortex and related subcortical systems. Etiologic studies have also identified candidate genes and prenatal and perinatal risk factors for ADHD. As the causes and course of ADHD are better understood, a new generation of medications is being developed for the disorder. Although stimulants are often effective in reducing the symptoms of the disorder, as a class they have limitations such as a lack of 24-hour-a-day coverage, unwanted side effects, potential for abuse, and lessened effectiveness in the context of some comorbidities. Therefore, the treatment characteristics of newer, more selective treatments such as atomoxetine should continue to be explored in ADHD.

(*J Clin Psychiatry* 2002;63[suppl 12]:3-9)

Attention-deficit/hyperactivity disorder (ADHD) is present in 3% to 10% of children and 1% to 6% of adults in the United States.¹ This high prevalence, the global impairment caused by the disorder, and its chronicity led the Centers for Disease Control and Prevention (CDC)² to identify ADHD as a serious public health problem in 1999. The most likely potential areas of impairment of ADHD in children include academic and social dysfunction and skill deficits. As children with ADHD mature, academic failures may lead to demoralization and poor self-esteem. Other risks include high rates of injuries, cigarette smoking, and substance use. In a subgroup, a risk of delinquency exists. Adults with persistent ADHD experience dysfunctions in occupational and vocational performance, continued social impairments, and higher rates of motor vehicle accidents.

Like all other psychiatric disorders, ADHD is a disorder for which there is no objective test. However, in recent years, research has made substantial advances in identifying the biological basis of ADHD. As the causes and course of ADHD are better understood, newer and more selective medications are being developed for the disorder.

PREVALENCE AND PERSISTENCE OF ADHD

Many studies³⁻¹⁶ of the worldwide prevalence of ADHD in children document that the prevalence is between 3% and 9%. Differences in the rates of ADHD (Table 1) among countries are usually methodological artifacts of the criteria used to define the disorder. In studies that followed up children who met criteria for hyperactivity and/or attention deficits, rates of persistence into adolescence and adulthood range from 8% to 85% (Table 2). Early studies,^{18,20,21} which used less formalized entry criteria that stressed hyperkinesia, as did the *Diagnostic and Statistical Manual of Mental Disorders*, Second Edition (DSM-II),²⁴ have the lowest rates of persistence, while more recent studies^{16,19} show fairly high rates of ADHD during follow-up. The changing terminology of ADHD, from hyperkinetic reaction of childhood in DSM-II²⁴ to attention-deficit disorder in DSM-III²⁵ to ADHD in DSM-III-R²⁶ and DSM-IV,²⁷ has reflected the changes in the conceptualization of the

From the Pediatric Psychopharmacology Unit, Psychiatry Service Massachusetts General Hospital and the Department of Psychiatry, Harvard Medical School, Boston.

Presented at the roundtable "Novel Treatments for Attention-Deficit/Hyperactivity Disorder in Children and Adults," which was held November 15-17, 2001, in Boston, Mass., and supported by an unrestricted educational grant from Eli Lilly and Company.

Corresponding author and reprints: Thomas J. Spencer, M.D., 15 Parkman St. WACC 725, Boston, MA 02114.

Table 1. Worldwide Prevalence of ADHD in School-Age Children*

Study	Region	Criteria	Prevalence (%)
Anderson et al., 1987 ⁷	New Zealand	DSM-III	6.7
Andros et al., 1995 ⁸	Spain	DSM-III-R	8.0
Baumgaertel et al., 1995 ⁹	Germany	DSM-III	9.6
Bird et al., 1988 ¹⁰	Puerto Rico	DSM-III	9.5–16.1
Buitelaar and Kooij, 2000 ⁶	Netherlands	DSM-IV	7.8
Esser et al., 1990 ⁷	London, England	DSM-III-R	1.7
Esser et al., 1990 ⁷	Manheim, Germany	DSM-III-R	4.2
Pellmar et al., 1992 ¹¹	United States	DSM-III-R	2.5–4.0
Rohde et al., 1999 ¹²	Brazil	DSM-IV	5.8
Schaffer et al., 1996 ¹³	United States	DSM-III-R	4.1
Szatmari, 1989 ¹⁰	Ontario, Canada	DSM-III	6.3

*Adapted with permission from Goldman et al.¹¹ Abbreviation: DSM = *Diagnostic and Statistical Manual of Mental Disorders*.

fundamental characteristics of this disorder. On the basis of the DSM-III-R criteria, more than 50% of patients no longer meet the full diagnostic criteria by age 20.²⁸ With the DSM-IV childhood criteria—that is, 6 of 9 of either hyperactive or inattentive symptoms—the rate of persistence is similar.²⁹ Although the DSM-IV includes the diagnosis of attention-deficit/hyperactivity disorder in partial remission for patients who have symptoms that cause functional impairment but are too few to meet the full diagnostic criteria, the DSM-IV continues to treat ADHD as a traditional psychiatric disorder with a single set of symptoms that characterize the disorder across the life span. Moreover, because adults in the normal population have fewer ADHD symptoms with age, Murphy and Barkley²⁹ have proposed that the DSM-IV criteria are too stringent for adults.

Barkley¹¹ has argued that ADHD more closely resembles a developmental disability such as mental retardation or dyslexia than a traditional psychiatric disorder. Because individuals with developmental disabilities experience delays in the rate at which a trait develops, not absolute losses of function, developmental disabilities are diagnosed on the basis of age-referenced criteria. Therefore, ADHD, if viewed as a developmental disability, should be diagnosed relative to characteristics of the individual's age group. Barkley et al.²⁹ compared diagnoses of ADHD using DSM criteria with those using developmental disorder criteria. He demonstrated that, depending on which model was applied, there was a difference in the persistence of ADHD into adulthood. When strict DSM-IV criteria were used, 58% of children with ADHD had the disorder by age 21. When developmentally referenced criteria and reports by others about the individual were used, the rate of persistence to adulthood was 66%.

How the rate of persistence of ADHD is judged also depends on the definition of remission. The mood disorder literature has a long tradition of examining subthreshold conditions and their relationship to function-

ality. For example, individuals with mania who no longer meet full criteria are nevertheless often not fully socially functional. In studies on mania, Keck and colleagues³¹ have described syndromal, symptomatic, and functional remission. Biederman and colleagues²⁶ have shown that, if these definitions of remission are used for ADHD, about 60% of individuals with childhood-onset ADHD no longer meet full diagnostic criteria for ADHD, i.e., have achieved syndromal remission, at age 20 years (Figure 1). Another 30% may not meet full diagnostic criteria but continue to have enough symptoms to have an impairing subthreshold condition, i.e., have achieved symptomatic remission. However, when remission of ADHD is defined as functional improvement to the point of having fewer than 5 symptoms and a score greater than 60 on the Global Assessment of Functioning Scale,²⁸ only 10% are found to be free of ADHD-associated functional impairment.

DIFFERENTIAL DIAGNOSIS OF ADHD

ADHD is a distinct disorder; impairments characteristic of ADHD are present in the absence of comorbid conditions. However, conditions such as conduct disorder, oppositional defiant disorder, major depressive disorder, bipolar disorder, anxiety disorders, substance-related disorders, and learning disabilities may mimic or, more commonly, coexist with ADHD. Before making the diagnosis of ADHD, physicians should collect reports from more than one source (e.g., teachers and parents), review school records, interview the individual, and conduct medical, psychological, and educational tests.³³ A patient's history and examination can determine whether the individual's seeming inattention or impulsivity is caused by a visual or auditory impairment. Other medical conditions, especially endocrine disorders such as hypothyroidism and hyperthyroidism, can have symptoms similar to those of ADHD but are rare in children. Because ADHD begins in childhood, this disorder's onset typically predates thyroid abnormalities, which generally occur later in life. Sleep disorders should also be ruled out as the cause of attention problems before the diagnosis of ADHD is made. During the individual's assessment, physicians should also determine whether the use of a medication, illegal substance, or alcohol is causing the symptoms of inattention, hyperactivity, or impulsivity.

Other mental disorders can cause impairments in social and occupational functioning similar to those associated with ADHD. However, these disorders can be distinguished from ADHD because they have additional symptoms and because ADHD exists in states in which these other disorders are absent. Individuals with conduct disorder differ from those with ADHD by exhibiting persistent antisocial behavior such as lying, cheating, and stealing. Individuals with oppositional defiant disorder

Table 2. Rates of Persistence of Attention-Deficit/Hyperactivity Disorder in Follow-Up Studies*

Study	Population (N)	Criteria at Entry	Criteria at Follow-Up	Time to Follow-Up (y)	Mean Age at Follow-Up (y)	Prevalence (%)
Barkley et al., 1990 ⁶	123	Hyperactivity scales	DSM-IV ADHD	8	14.9	72
Borland and Heckman, 1976 ⁵	20	Hyperactivity scales	Hyperactivity scales ^b	20–25	30.4	10
Blideman et al., 1996 ¹⁰	128	DSM-III-R ADHD	DSM-III-R ADHD	4	14.5	85
Canwell and Baker, 1987 ⁷	202	DSM-III ADD	DSM-III ADD	3–4	9.0	33
Gittelman et al., 1985 ¹⁸	101	DSM-II hyperkinetic reaction of childhood	DSM-III ADD-H	9	18.3	31
Hait et al., 1995 ¹⁹	106	DSM-III-R ADHD	DSM-III-R ADHD	4	10.4	77
Mannuzza et al., 1991 ⁷	101	DSM-II hyperkinetic reaction of childhood	ADD	8–14	18.5	43
Mannuzza et al., 1993 ⁷	91	DSM-II hyperkinetic reaction of childhood	DSM-III-R ADHD	13–19	25.5	8
Offord et al., 1992 ²⁷	48	DSM-III ADD	DSM-III ADD	4	NA	34 ^c
Weiss et al., 1985 ²³	61	Hyperactivity scales	Hyperactivity scales ^d	15	25.1	36


*Abbreviations: ADD = attention deficit disorder, ADD-H = attention deficit disorder with hyperactivity, ADHD = attention-deficit/hyperactivity disorder, DSM = *Diagnostic and Statistical Manual of Mental Disorders*. NA = not available.

^bAt least 6 symptoms of hyperactivity.

^cWeighted data were used.

^dAt least 1 moderately or severely disabling symptom.

Figure 1. Age-Specific Prevalence of the Remission of DSM-III-R Attention-Deficit/Hyperactivity Disorder*



*Reprinted with permission from Blideman et al.¹⁰ Abbreviation: DSM-III-R = *Diagnostic and Statistical Manual of Mental Disorders*, Third Edition Revised.

often are easily annoyed and exhibit hostile, defiant, spiteful, and negativistic behaviors. Like individuals with ADHD, those with major depressive disorder may show signs of inattention and become easily upset. However, they must have also experienced at least 2 weeks of depressed mood or loss of interest or pleasure in most activities, and they complain of easy fatigue and loss of energy, not hyperactivity. Mild or fluctuant cases of bipolar disorder, especially in children, can be difficult to distinguish from ADHD, but children with substantial bipolar disorder have clear mood impairments, including elation, grandiosity, severe irritability and anger, a decreased need for sleep, hypersexuality, and racing thoughts.³⁴ In anxiety disorders, hyperactive behaviors such as fidgeting and inattentive behaviors such as off-task behaviors are accompanied by persistent fears and worries.

The impairment of adaptive functioning in mental retardation is more severe than the social, academic, and occupational impairment associated with ADHD and occurs with an impairment of general intellectual functioning (i.e., an intelligence quotient [IQ] ≤ 75). Like individuals with ADHD, those with pervasive developmental disorders such as autism and Asperger's disorder may exhibit hyperactivity or fidgeting and impaired social, academic, and occupational functioning. However, individuals with pervasive developmental disorders also exhibit a severe disinterest or inability to participate in social interaction or limited and stereotyped behavior, interests, and activities. Although, like ADHD, learning disorders may impair academic or occupational functioning, these disorders, which are frequently comorbid with ADHD, are characterized by a specific learning impairment as evidenced by a significant discrepancy between individuals' performance on a standardized test in reading, mathematics, or written expression and their education and intelligence.


ETIOLOGY OF ADHD

No single etiology has been identified for ADHD, and findings are consistent with a multifactorial hypothesis. Indeed, all neuropsychiatric conditions are thought to be caused by a complex combination of environmental, genetic, and biological factors. Therefore, the proposed etiologies related to prenatal and perinatal risk factors, genetics, and neurobiological deficits may all contribute to the pathophysiology of ADHD in different individuals.

Prenatal and Perinatal Risk Factors

Mick and colleagues³⁵ used odds ratios, in which 1 is neutral, to examine risk factors for ADHD in siblings (Figure 2). To distinguish whether each of these factors independently contributes to the risk of developing ADHD,

Figure 2. Results From a Logistic Regression Model of Odds Ratios for Prenatal and Perinatal Risk Factors for Attention-Deficit/Hyperactivity Disorder Versus Controls*



*Data from Mick et al.⁴³ Abbreviations: ADHD = attention-deficit/hyperactivity disorder, CD = conduct disorder, IQ = intelligence quotient.

[†]1 is neutral.

they used a mathematical model to separate each factor. For example, individuals with ADHD often use alcohol and/or cigarettes; therefore, one could suppose that having a parent with ADHD may contribute to the identification of exposure to alcohol and cigarettes in utero as risk factors for developing ADHD. However, with their analysis, Mick et al. found that, independent of whether a parent has ADHD, exposure to cigarettes or alcohol in utero is a specific teratogen for ADHD that, like low weight at birth, increases the risk of developing ADHD 2- to 3-fold. Parental ADHD, the genetic factor, increased the risk of developing this condition 8-fold. Brain injuries that occur in utero also contributed to the risk of developing ADHD. Socioeconomic status, the mother's age at the time of the child's birth, and parental IQ contributed little to either the risk of developing or protection from the disorder.

Heritability

Studies of dizygotic and monozygotic twins who have grown up in the same environment have been examined to determine the heritability of ADHD (Table 3). A heritability of 0 means that there is no genetic input, and a heritability of 1 means that the characteristic or disorder is completely determined by genetics. Because the identical twins have the same genes and the fraternal twins share only one half of their genes, these studies help to determine the genetic versus the environmental contribution. The mean heritability of ADHD from these studies is approximately 0.75, which means that about 75% of the etiologic contribution to this disorder is genetic. Therefore, ADHD is more attributable to genetic factors than are depression (0.39 heritability),⁴⁵ generalized anxiety disorder (0.32 heritability),⁴⁶ breast cancer (0.27 heritability),⁴⁷ and asthma (0.39 heritability).⁴⁸

One reason for the variation in the heritability of ADHD in these studies is that they used different numbers

of items to calculate heritability, from 2 or 3 items from the Rutter A scale to all 14–18 items in the ADHD criteria of various DSM editions. Generally, the studies that used more items showed a higher heritability than did the studies that used only 2 or 3 items. If corrected for unreliability on the basis of the type of scale and number of items used in each of these studies, the heritability of ADHD might be even higher than 0.75.

Candidate Genes

Once the extent of the genetic contribution to ADHD had been revealed, researchers began trying to identify the candidate genes. The association between ADHD and several genes, including those regulating dopamine, norepinephrine, serotonin, γ -aminobutyric acid (GABA), and androgens, has been studied.⁴⁹ While some studies⁵⁰ have not found an association between any of these genes and ADHD,⁵¹ most did.

The gene association that has been most widely confirmed is the 7-repeat allele of the D₄ dopamine receptor gene (*DRD4*7*).^{52,53} *DRD4*7* is a defective gene found in about 30% of the general population and about 50% to 60% of the population with ADHD.⁵⁴ Multiple replication of a specific amino acid sequence in *DRD4*7* has been related to a deficiency in translating the dopaminergic signal to the second messenger system. Specifically, there is an incomplete coupling of the receptor to the guanine nucleotide complex in the third cytoplasmic loop of the protein.⁵⁴ Other research⁵⁵ on the D₄ receptor has shown that, in addition to dopamine, both epinephrine and norepinephrine are agonists at *DRD4*7*. Therefore, medications that affect either of these catecholamines could also affect this dopaminergic system.

Model of Executive Dysfunctions

The change in the nosology from hyperactivity early in the 20th century to ADHD by the early 1980s paralleled the shift in thinking from the belief that this disorder was caused by primarily bad behavior to the hypothesis that the disorder represents a cognitive brain problem that results in associated maladaptive behavior. Now we have a more sophisticated model of the brain dysfunctions that lead to problems with attention, impulsivity, and hyperactivity.

Barkley⁴⁶ proposed a model of executive dysfunctions located in the prefrontal cortex that explains the cognitive and behavioral deficits associated with ADHD. Barkley's model comprises 5 major executive functions that enable individuals to recognize and control their actions to achieve a goal: response inhibition, nonverbal working memory, verbal working memory, self-regulation of emotion and motivation, and reconstitution. Response inhibition delays and interrupts responses and controls interference to allow individuals to control verbal and motor impulses. Nonverbal working memory enables a person to have a sense of the past and future and a cognitive

Table 3. Average Genetic Contribution of Attention-Deficit/Hyperactivity Disorder From Studies of Twins Between the Ages of 4 and 16 Years*

Study	Twin Pairs (N)	Diagnosis	Measure	Heritability
Eaves et al. 1997 ³²	1355	Hyperactivity	Mothers' completion of Rutter A scale	0.60-0.80
Edelbrock et al. 1995 ³⁸	181	Attention problems	Parents' completion of CBCL	0.66
Gillis et al. 1992 ²⁸	74	DSM-III-R ADHD	Structured interviews with parents using DICA	0.91
Gjone et al. 1996 ³⁰	915	Attention problems	Mothers' completion of CBCL	0.73-0.79
Hudziak et al. 2000 ⁴⁴	492	Attention problems	Parents' completion of CBCL	0.60-0.68
Levy et al. 1997 ⁴²	1634	DSM-III-R ADHD	DSM-III-R-based maternal rating scale	0.75-0.91
Sherman et al. 1997 ⁴³	288	DSM-III ADD-H and DSM-III-R ADHD	Teacher rating form of MTFS and structured maternal interviews using DICA-R	0.73-0.89
Thapar et al. 1995 ⁴⁵	281	Hyperactivity	Mothers' completion of Rutter A scale	0.88

*Adapted with permission from Thapar et al.⁴⁶ Abbreviations: CBCL = Child Behavior Checklist, DICA = Diagnostic Interview for Children and Adolescents, DSM = Diagnostic and Statistical Manual of Mental Disorders, MTFS = Minnesota Twin Family Study.

awareness of self. Verbal working memory gives people the ability to internalize receptive and expressive language for self-questioning, self-description, and establishing rules for behavior. Together, the nonverbal and verbal working memories provide the ability for reading comprehension and moral conduct. Through internalizing visual and verbal stimuli, the 2 working memories also lead to the development of the self-regulation of emotion and motivation, which provides individuals the ability to control their emotions and the motivation and persistence necessary to meet their goals. The last major executive function, reconstitution, is a form of play that allows people to analyze the experiences in their working memories to synthesize new responses, which they accept or reject based on the likelihood that the response can help them to achieve their goal. Barkley has proposed that, of these 5 executive functions, response inhibition is most obviously deficient in individuals with ADHD and that this deficit may lead to the impairments observed in the psychological and social abilities associated with the other 4 executive functions.

Brain Imaging

Neurologic differences have been documented in the brains of individuals with and without ADHD through structural and functional magnetic resonance imaging (fMRI). The circuits that control attention are smaller and less active in individuals with ADHD than in controls.³⁷ These circuits include the parts of the prefrontal cortex that control working memory, alerting, and response inhibition. Because these areas are also rich in catecholamine receptors, the belief that norepinephrine and dopamine are prominently involved in ADHD comes from not only medication and neurotransmitter studies but also studies of the affected brain areas.

Bush and colleagues³⁸ found differences in the function of the cognitive division of the anterior cingulate cortex in the brains of individuals with ADHD and controls without ADHD. In their study, unmedicated adults with ADHD and adults without ADHD were given the Counting Stroop test, a variation of the Color Stroop, which measures

response inhibition. During the Counting Stroop task, a set of 1 to 4 identical words appear on a screen, and subjects are told to identify the number of words on the screen by pressing 1 of 4 buttons, which, from left to right, represent the numbers 1-4. The neutral trials consist of sets of identical common animal names, while the interference trials include sets of identical number words that do not correspond with the number of words appearing on the screen. For example, the word 2 will appear in sets of only 1, 3, or 4. While subjects performed the Counting Stroop, fMRI measured the blood flow in their brains, specifically in the cingulate cortex, to determine which areas were being used during the task.

Metabolism increased in the area of the brain that was used while the task was being performed and diminished when the task was stopped. During a 4-minute span, subjects completed 30-second blocks of alternating neutral and interference trials, each of which contained 20 sets of words. This replication showed that the activity performed during the Counting Stroop is a distinct function that is controlled by a distinct part of the brain. According to the analysis of subjects' reaction times, adults with ADHD took longer to perform the task than the controls. The results of the fMRI showed that the 2 groups also activated different parts of the brain to complete the task. While adult controls activated the cognitive division of the anterior cingulate cortex during the task, adults with ADHD activated a fronto-striato-insular-thalamic network. The use of ancillary areas of the brain by individuals with ADHD demonstrates that, while the brain may compensate for its deficits, these compensations are not perfect and correlate with inefficient processing.³⁸

NEED FOR NEW TREATMENTS

While stimulants, the traditional medications for ADHD, are remarkably effective in the treatment of this disorder, their use has some limitations. For example, ADHD lasts 24 hours per day, but we lack 24-hour-per-day treatments. Immediate-release formulations of stimu-

lants must be taken in repeated doses throughout the day. The extended-release formulations of the stimulants are effective for 8 to 12 hours. While these longer acting formulations have been a major advance in our pharmacotherapeutic armamentarium, additional strategies must be employed to cover longer periods. In addition, stimulants have the potential for abuse and may not be optimal in several comorbid conditions such as tic disorders.

Because of stimulants' limitations, a number of alternative medications have been explored in ADHD. Tricyclic antidepressants (TCAs), which affect norepinephrine, may be efficacious in ADHD, but their action is not selective. The effects of TCAs on other neurotransmitter systems can cause side effects such as dry mouth, constipation, sedation, weight gain, changes in blood pressure, and delays in cardiac conduction and repolarization. Selective serotonin reuptake inhibitors (SSRIs) have also been explored as a possible treatment for ADHD, but they have shown no evidence of efficacy. Although antihypertensive medications may help with symptoms of ADHD, these drugs are complicated to use in children because they may be sedating and may cause hypertension if they are abruptly discontinued. Recently, researchers have explored the efficacy of the investigative nonstimulant atomoxetine in the treatment of ADHD. Atomoxetine, which was initially examined under the name tomozetine as an antidepressant, may be efficacious in ADHD⁵⁹ and appears to be a potent and specific norepinephrine reuptake inhibitor.⁶⁰

CONCLUSION

Developmentally sensitive, age-appropriate criteria would help clinicians to more accurately diagnose ADHD in both children and adults. As studies provide more insight into the genetic, environmental, and neurobiological causes of this disorder, the effects of medications on ADHD may be better understood. Expanded medication options will help physicians to choose the most effective and safest treatment for their patients with ADHD, thereby increasing effective therapy and reducing the wide range of ADHD-associated impairments.

Disclosure of off-label usage: The authors of this article have determined that, to the best of their knowledge, atomoxetine is not approved by the U.S. Food and Drug Administration for the treatment of attention-deficit/hyperactivity disorder.

REFERENCES

- Wendler PH, Wolf LE, Wasserstein J. Adults with ADHD: an overview. *Ann NY Acad Sci* 2001;931:1-16.
- Lesene C, Abramowitz A, Perot R, et al. Attention deficit/hyperactivity disorder: a public health research agenda. March 15, 2000. Available at: <http://www.ehc.gov/ncdd/adhd/adhpra.htm>. Accessed Feb 12, 2002.
- Anderson JC, Williams S, McGee R, et al. DSM-III disorders in preadolescent children: prevalence in a large sample from the general population. *Arch Gen Psychiatry* 1987;44:69-76.
- Andres Carrasco MA, Catala MA, Gomez-Beneyto M. Study of the prevalence of the attention deficit hyperactivity disorder in ten-year-old children living in the Valencia metropolitan area [in Spanish]. *Actas Luso Esp Neurol Psiquiatr Cienc Afines* 1995;23:184-188.
- Baumgaertel A, Wolbach ML, Dietrich M. Comparison of diagnostic criteria for attention deficit disorders in a German elementary school sample. *J Am Acad Child Adolesc Psychiatry* 1998;34:629-638.
- Butelaar JK, Kooij JJ. Attention deficit hyperactivity disorder (ADHD) etiology, diagnosis and treatment [in Dutch]. *Ned Tijdschr Geneesk* 2000;144:1716-1723.
- Essex G, Schmidt MH, Woerner W. Epidemiology and course of psychiatric disorders in school-age children: results of a longitudinal study. *J Child Psychol Psychiatry* 1990;31:243-263.
- Rohde LA, Biederman J, Bursello EA, et al. ADHD in a school sample of Brazilian adolescents: a study of prevalence, comorbid conditions, and impairments. *J Am Acad Child Adolesc Psychiatry* 1999;38:716-722.
- Shaffer D, Fisher P, Dulcan MK, et al. The NIMH Diagnostic Interview Schedule for Children Version 2.3 (DISC-2.3): description, acceptability, prevalence rates, and performance in the MECA Study. *J Am Acad Child Adolesc Psychiatry* 1996;35:865-877.
- Szatmari P, Offord DR, Boyle MH, Ontario Child Health Study: prevalence of attention deficit disorder with hyperactivity. *J Child Psychol Psychiatry* 1989;30:219-230.
- Goldman LS, Genel M, Bezman RJ, et al. for the Council on Scientific Affairs, American Medical Association. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. *JAMA* 1998;279:1100-1107.
- Bird HR, Canino G, Rubio-Stipe M, et al. Estimates of the prevalence of childhood maladjustment in a community survey in Puerto Rico: the use of combined measures. *Arch Gen Psychiatry* 1988;45:1120-1126.
- Pellmar WE Jr, Nagy EM, Greenslade KE, et al. Teacher ratings of DSM-III-R symptoms for the disruptive behavior disorders. *J Am Acad Child Adolesc Psychiatry* 1992;31:210-218.
- Barkley RA, Fischer M, Edelbrock CS, et al. The adolescent outcome of hyperactive children diagnosed by research criteria, pt 1: an 8 year prospective follow-up study. *J Am Acad Child Adolesc Psychiatry* 1990;29:546-557.
- Borland BL, Hechtman HK. Hyperactive boys and their brothers: a 25-year follow-up study. *Arch Gen Psychiatry* 1976;33:669-675.
- Biederman J, Faraone S, Milberger S, et al. A prospective 4-year follow-up study of attention-deficit hyperactivity disorder and related disorders. *Arch Gen Psychiatry* 1996;53:437-446.
- Cantwell DP, Baker L. Clinical significance of childhood communication disorders: perspectives from a longitudinal study. *J Child Neurol* 1987;2:257-264.
- Gittelman R, Manuagaza S, Shenker R, et al. Hyperactive boys almost grown up, I: psychiatric status. *Arch Gen Psychiatry* 1985;42:937-947.
- Hart EL, Lalley BB, Loeber R, et al. Developmental change in attention-deficit hyperactivity disorder in boys: a four-year longitudinal study. *J Abnorm Child Psychol* 1995;23:729-749.
- Manuagaza S, Klein RG, Bonaguidi N, et al. Hyperactive boys almost grown up, V: replication of psychiatric status. *Arch Gen Psychiatry* 1991;48:77-83.
- Manuagaza S, Klein RG, Bessler A, et al. Adult outcome of hyperactive boys: educational achievement, occupational rank, and psychiatric status. *Arch Gen Psychiatry* 1993;50:565-576.
- Offord DR, Boyle MH, Racine YA, et al. Outcome, prognosis, and risk in a longitudinal follow-up study. *J Am Acad Child Adolesc Psychiatry* 1992;31:916-923.
- Weiss G, Hechtman L, Milroy T, et al. Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. *J Am Acad Child Psychiatry* 1985;24:211-220.
- American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. Second Edition. Washington, DC: American Psychiatric Association; 1968.
- American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. Third Edition. Washington, DC: American Psychiatric Association; 1980.
- American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987.
- American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
- Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms

- of attention deficit hyperactivity disorder: impact of remission definition and symptom type. *Am J Psychiatry* 2000;157:816-818.
29. Barkley RA, Fischer M, Fischer K, et al. Persistence of attention deficit hyperactivity disorder into adulthood as a function of reporting source and definition of disorder. *J Abnorm Psychol* 2002;111:279-289.
 30. Murphy K, Barkley RA. Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers: implications for clinical diagnosis. *J Atten Disord* 1996;1:147-161.
 31. Barkley RA. *Attention-Deficit/Hyperactivity Disorder: A Handbook for Diagnosis and Treatment*. New York, NY: Guilford Press; 1990.
 32. Keck PE Jr, McElroy SL, Strakowski SM, et al. 12-Month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. *Am J Psychiatry* 1998;155:646-652.
 33. Dunne JE. Attention-deficit/hyperactivity disorder and associated childhood disorders. *Prim Care* 1999;26:349-372.
 34. Geller B, Williams M, Zimmerman B, et al. Prepubertal and early adolescent bipolarity differentiated from ADHD by manic symptoms, grandiose delusions, ultra-rapid or ultradian cycling. *J Affect Disord* 1998;51:81-91.
 35. Muck E, Bieleman J, Ponce J, et al. Impact of low birth weight on attention-deficit/hyperactivity disorder. *J Dev Behav Pediatr* 2002;23:16-22.
 36. Thapar A, Holmes J, Poulton K, et al. Genetic basis of attention deficit and hyperactivity. *Br J Psychiatry* 1999;174:105-111.
 37. Eaves LJ, Silberg JL, Meyer JM, et al. Genetics and developmental psychopathology. 2: the main effects of genes and environment on behavioral problems in the Virginia Twin Study of Adolescent Behavioral Development. *J Child Psychol Psychiatry* 1997;38:965-980.
 38. Edelbrock C, Rende R, Plomin R, et al. A twin study of competence and problem behavior in childhood and early adolescence. *J Child Psychol Psychiatry* 1995;36:775-785.
 39. Gillis JJ, Giger JW, Pennington BF, et al. Attention deficit disorder in reading-disabled twins: evidence for a genetic etiology. *J Abnorm Child Psychol* 1992;20:305-315.
 40. Gjone H, Stevenson J, Sundet JM. Genetic influence on parent-reported attention-related problems in a Norwegian general population twin sample. *J Am Acad Child Adolesc Psychiatry* 1996;35:588-596; discussion 596-598.
 41. Hudziak JJ, Rudiger LP, Neale MC, et al. A twin study of inattentive, aggressive, and anxious/depressed behaviors. *J Am Acad Child Adolesc Psychiatry* 2000;39:469-476.
 42. Levy F, Hay DA, McStephen M, et al. Attention-deficit hyperactivity disorder: a category or a continuum? genetic analysis of a large-scale twin study. *J Am Acad Child Adolesc Psychiatry* 1997;36:731-744.
 43. Shenau DK, McCue MK, Iacono WG. Twin concordance for attention deficit hyperactivity disorder: a comparison of teachers' and mothers' reports. *Am J Psychiatry* 1997;154:552-555.
 44. Thapar A, Harris A, McGuffin P. Childhood hyperactivity scores are highly heritable and show sibling competition effects: twin study evidence. *Behav Genet* 1995;25:537-544.
 45. Kendler KS, Prescott CA. A population-based twin study of lifetime major depression in men and women. *Arch Gen Psychiatry* 1999;56:39-44.
 46. Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. *Am J Psychiatry* 2001;158:1568-1578.
 47. Henniszka K, Mutanen P. Genetic epidemiology of multistage carcinogenesis. *Mutat Res* 2001;473:11-21.
 48. Palmer LJ, Knauman MW, Devitt ML, et al. Familial aggregation and heritability of adult lung function: results from the Busselton Health Study. *Eur Respir J* 2001;17:696-702.
 49. Comings DE. Clinical and molecular genetics of ADHD and Tourette syndrome: two related polygenic disorders. *Am N Y Acad Sci* 2001;931:50-83.
 50. Castellanos FX, Lau E, Tayebi N, et al. Lack of an association between a dopamine-4 receptor polymorphism and attention-deficit/hyperactivity disorder: genetic and brain morphometric analyses. *Mol Psychiatry* 1998;3:431-434.
 51. Todd RD, Neuman RJ, Lobos EA, et al. Lack of association of dopamine D4 receptor gene polymorphisms with ADHD subtypes in a population sample of twins. *Am J Med Genet* 2001;105:452-458.
 52. Faraone SV, Biederman J, Wittchen BS, et al. Dopamine D4 gene 7-repeat allele and attention deficit hyperactivity disorder. *Am J Psychiatry* 1999;156:768-770.
 53. Mill J, Curran S, Kent L, et al. Attention deficit hyperactivity disorder (ADHD) and the dopamine D4 receptor gene: evidence of association but no linkage in a UK sample. *Mol Psychiatry* 2001;6:440-444.
 54. Lachet JB, Barr CL, Kennedy JL, et al. A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. *Hum Mol Genet* 1993;2:767-773.
 55. Lanau F, Zenner MT, Civelli O, et al. Epinephrine and norepinephrine act as potent agonists at the recombinant human dopamine D4 receptor. *J Neurochem* 1997;68:804-812.
 56. Barkley RA. *ADHD and the Nature of Self-Control*. New York, NY: Guilford; 1997.
 57. Faraone SV, Biederman J. The neurobiology of attention deficit hyperactivity disorder. In: Charney DS, Nestler EJ, Bunney BS, eds. *Neurobiology of Mental Illness*. New York, NY: Oxford University Press; 1999: 788-801.
 58. Bush G, Frazier JA, Rauch SL, et al. Anterior cingulate cortex dysfunction in attention-deficit/hyperactivity disorder revealed by fMRI and the Counting Stroop. *Biol Psychiatry* 1999;45:1542-1552.
 59. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. *Pediatrics* 2001;108:E83.
 60. Zerbe R, Rowe H, Enas G, et al. Clinical pharmacology of tomooxetine, a potential antidepressant. *J Pharmacol Exp Ther* 1985;232:149-143.
 61. Findling RL. Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series. *J Child Adolesc Psychopharmacol* 1996;6:165-175.